

Title (en)
INHIBITORS OF THE LECTIN COMPLEMENT PATHWAY (LCP) AND THEIR USE

Title (de)
INHIBITOREN DES LECTIN-KOMPLEMENTSYSTEMS (LCP) UND IHRE VERWENDUNG

Title (fr)
INHIBITEURS DE LA VOIE DU COMPLEMENT A LECTINE (LPC) ET UTILISATION DE CEUX-CI

Publication
EP 1204419 A1 20020515 (EN)

Application
EP 00954011 A 20000814

Priority
• US 0022123 W 20000814
• US 14881599 P 19990813

Abstract (en)
[origin: WO0112212A1] The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both *in vitro* and *in vivo* methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin (MBL) receptor antagonist to inhibit lectin complement pathway associated complement activation. The mannan binding lectin receptor antagonist may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin receptor antagonist. The mannan binding lectin receptor antagonist is an isolated mannan binding lectin that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation.

IPC 1-7
A61K 38/16; **A61K 39/395**; **A61P 9/10**; **A61P 11/00**; **A61P 37/06**; **A61P 7/02**; **A61P 19/02**; **A61P 9/00**; **A61P 37/00**

IPC 8 full level
G01N 33/50 (2006.01); **A61K 36/48** (2006.01); **A61K 38/00** (2006.01); **A61K 38/16** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 7/02** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 17/02** (2006.01); **A61P 19/02** (2006.01); **A61P 37/00** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C07K 16/18** (2006.01); **G01N 33/15** (2006.01); **A61K 38/12** (2006.01)

CPC (source: EP)
A61K 38/168 (2013.01); **A61P 7/02** (2017.12); **A61P 9/00** (2017.12); **A61P 9/04** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 17/02** (2017.12); **A61P 19/02** (2017.12); **A61P 37/00** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C07K 16/18** (2013.01); **A61K 38/00** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/55** (2013.01)

Citation (search report)
See references of WO 0112212A1

Citation (examination)
• WO 9531728 A1 19951123 - BEKI AB [SE], et al
• HASAN ET AL: "Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells", PNAS, vol. 95, March 1998 (1998-03-01), pages 3615 - 3620

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0112212 A1 20010222; AU 6637000 A 20010313; AU 781805 B2 20050616; CA 2380979 A1 20010222; EP 1204419 A1 20020515; JP 2003507338 A 20030225

DOCDB simple family (application)
US 0022123 W 20000814; AU 6637000 A 20000814; CA 2380979 A 20000814; EP 00954011 A 20000814; JP 2001516557 A 20000814